DK2032156T3 - Sammensætninger og fremgangsmåder til levering af oxygen - Google Patents

Sammensætninger og fremgangsmåder til levering af oxygen

Info

Publication number
DK2032156T3
DK2032156T3 DK07795174.7T DK07795174T DK2032156T3 DK 2032156 T3 DK2032156 T3 DK 2032156T3 DK 07795174 T DK07795174 T DK 07795174T DK 2032156 T3 DK2032156 T3 DK 2032156T3
Authority
DK
Denmark
Prior art keywords
procedures
compositions
delivering oxygen
delivering
oxygen
Prior art date
Application number
DK07795174.7T
Other languages
English (en)
Inventor
Emily Weinert
Jonathan A Winger
Stephen P L Cary
Michael A Marletta
Elizabeth M Boon
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK2032156T3 publication Critical patent/DK2032156T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C07K14/43545—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/102499—Blood gas standard or control

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07795174.7T 2006-05-22 2007-05-21 Sammensætninger og fremgangsmåder til levering af oxygen DK2032156T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92150506P 2006-05-22 2006-05-22
PCT/US2007/012184 WO2007139791A2 (en) 2006-05-22 2007-05-21 Compositions and methods for the delivery of oxygen

Publications (1)

Publication Number Publication Date
DK2032156T3 true DK2032156T3 (da) 2013-02-18

Family

ID=38779160

Family Applications (4)

Application Number Title Priority Date Filing Date
DK07795153.1T DK2040740T3 (da) 2006-05-22 2007-05-21 Sammensætninger og fremgangsmåder til levering af nitrogenmonoxid
DK11189807.8T DK2463294T3 (da) 2006-05-22 2007-05-21 Sammensætninger og fremgangsmåder til levering af nitrogenoxid
DK11189814.4T DK2463297T3 (da) 2006-05-22 2007-05-21 Sammensætninger og fremgangsmåder til levering af oxygen
DK07795174.7T DK2032156T3 (da) 2006-05-22 2007-05-21 Sammensætninger og fremgangsmåder til levering af oxygen

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK07795153.1T DK2040740T3 (da) 2006-05-22 2007-05-21 Sammensætninger og fremgangsmåder til levering af nitrogenmonoxid
DK11189807.8T DK2463294T3 (da) 2006-05-22 2007-05-21 Sammensætninger og fremgangsmåder til levering af nitrogenoxid
DK11189814.4T DK2463297T3 (da) 2006-05-22 2007-05-21 Sammensætninger og fremgangsmåder til levering af oxygen

Country Status (13)

Country Link
US (7) US8404632B2 (da)
EP (7) EP2474554A3 (da)
JP (5) JP5698905B2 (da)
CN (5) CN101495506B (da)
AU (2) AU2007268028B2 (da)
BR (2) BRPI0711901A2 (da)
CA (2) CA2653101C (da)
DK (4) DK2040740T3 (da)
ES (4) ES2611157T3 (da)
HK (1) HK1129688A1 (da)
IN (2) IN2013MN00600A (da)
NZ (4) NZ594457A (da)
WO (2) WO2007139791A2 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2040740T3 (da) 2006-05-22 2014-12-01 Univ California Sammensætninger og fremgangsmåder til levering af nitrogenmonoxid
US20110243849A1 (en) * 2010-04-02 2011-10-06 Marletta Michael A Heme-binding photoactive polypeptides and methods of use thereof
EP3922643A1 (en) * 2013-01-07 2021-12-15 Omniox, Inc. Polymeric forms of h-nox proteins
US20180243364A1 (en) * 2015-03-17 2018-08-30 Omniox, Inc. Modulation of tumor immunity by protein-mediated 02 delivery
JP2019511567A (ja) * 2016-02-16 2019-04-25 オムニオックス， インコーポレイテッド 脳卒中と関連する低酸素状態の調節
JP6467073B2 (ja) * 2018-01-04 2019-02-06 オムニオクス， インコーポレイテッド Ｈ−ｎｏｘタンパク質の重合体形態
WO2020037052A1 (en) 2018-08-15 2020-02-20 Omniox, Inc. H-nox proteins for treating cardiovascular and pulmonary conditions
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
CN118178645A (zh) 2019-10-18 2024-06-14 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
WO2021087064A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
JP2023509881A (ja) 2019-12-24 2023-03-10 カルナバイオサイエンス株式会社 ジアシルグリセロールキナーゼ調節化合物
EP4103285A2 (en) 2020-02-14 2022-12-21 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
KR20230006891A (ko) 2020-05-01 2023-01-11 길리애드 사이언시즈, 인코포레이티드 Cd73를 억제하는 2,4-다이옥소피리미딘 화합물
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CR20230585A (es) 2021-06-23 2024-02-19 Gilead Sciences Inc Compuestos Moduladores de Diacilglicerol Quinasa.
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
AU2022376954A1 (en) 2021-10-29 2024-05-02 Gilead Sciences, Inc. Cd73 compounds
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ｉｋａｒｏｓ鋅指家族降解劑及其用途
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6022849A (en) * 1987-05-16 2000-02-08 Baxter Biotech Technology Saarl Mutant recombinant hemoglobins containing heme pocket mutations
US5731454A (en) 1990-02-12 1998-03-24 Virginia Commonwealth University Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
WO1995027040A1 (en) * 1994-04-01 1995-10-12 Unisyn Technologies, Inc. Culture media additives for hollow fiber bioreactors
DE69831248T2 (de) * 1997-02-28 2006-04-13 The Regents Of The University Of California, Oakland Verfahren und zusammensetzungen zur optimierung des sauerstofftransportes in zellfreien systemen
JP4512673B2 (ja) 1997-05-02 2010-07-28 バクスター バイオテク テクノロジー エス． アー． アール． エル． 増大した可溶性発現および／または低下した一酸化窒素の排出を伴うヘモグロビン変異体
DE19837015C2 (de) * 1998-08-14 2003-03-20 Vasopharm Biotech Gmbh Isolierte und gereinigte humane lösliche Guanylylcyclase alpha1/beta1 (hsGCalpha1/beta1)
US6773613B1 (en) * 1998-10-15 2004-08-10 Sangart, Inc. Method for production of stroma-free hemoglobin
RU2271216C2 (ru) * 1999-12-22 2006-03-10 Дзе Скриппс Рисерч Инститьют Модуляторы ангиогенеза и проницаемости сосудов
JP2004529603A (ja) * 2000-06-29 2004-09-30 インサイト・ゲノミックス・インコーポレイテッド アデニリルシクラーゼ及びグアニリルシクラーゼ
US20030096240A1 (en) * 2000-09-19 2003-05-22 Ferid Murad Genomic organization of mouse and human sGC
US6780849B2 (en) * 2000-12-21 2004-08-24 Scimed Life Systems, Inc. Lipid-based nitric oxide donors
US20030153491A1 (en) 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
CN102268094A (zh) * 2002-08-30 2011-12-07 比奥雷克西斯药物公司 被修饰的转铁蛋白抗体的融合蛋白
CN1660100A (zh) * 2002-12-09 2005-08-31 上海倍艺医药科技有限公司 一种治疗糖尿病及其并发症的药物
DK2040740T3 (da) 2006-05-22 2014-12-01 Univ California Sammensætninger og fremgangsmåder til levering af nitrogenmonoxid

Also Published As

Publication number Publication date
IN2013MN00600A (da) 2015-06-12
EP2040740A2 (en) 2009-04-01
IN2013MN00601A (da) 2015-06-12
US20150376250A1 (en) 2015-12-31
JP2009538133A (ja) 2009-11-05
BRPI0711767B8 (pt) 2021-05-25
CN101495506A (zh) 2009-07-29
ES2525226T3 (es) 2014-12-19
WO2007139767A2 (en) 2007-12-06
US20130289252A1 (en) 2013-10-31
JP5698906B2 (ja) 2015-04-08
US9493526B2 (en) 2016-11-15
DK2463294T3 (da) 2017-01-16
BRPI0711767B1 (pt) 2018-05-15
NZ573003A (en) 2012-06-29
JP2009538134A (ja) 2009-11-05
WO2007139767A3 (en) 2008-02-07
US10202428B2 (en) 2019-02-12
CA2653080A1 (en) 2007-12-06
EP2463297A1 (en) 2012-06-13
AU2007268028A1 (en) 2007-12-06
EP2463294B1 (en) 2016-10-19
US20130288970A1 (en) 2013-10-31
EP2463294A1 (en) 2012-06-13
US20100266673A1 (en) 2010-10-21
CN101495134A (zh) 2009-07-29
WO2007139791A2 (en) 2007-12-06
BRPI0711901A2 (pt) 2012-03-06
EP2032156A2 (en) 2009-03-11
US20170267732A1 (en) 2017-09-21
JP6118296B2 (ja) 2017-04-19
AU2007268052A1 (en) 2007-12-06
AU2007268028B2 (en) 2013-03-14
EP2040740A4 (en) 2009-10-21
NZ594456A (en) 2013-06-28
JP2015007108A (ja) 2015-01-15
JP6458070B2 (ja) 2019-01-23
CN106075388A (zh) 2016-11-09
CN106075388B (zh) 2021-06-29
AU2007268052B2 (en) 2013-07-04
CN101495506B (zh) 2016-08-10
US20100285104A1 (en) 2010-11-11
CN104689300B (zh) 2018-06-05
JP5698905B2 (ja) 2015-04-08
DK2463297T3 (da) 2017-01-09
CN108273040A (zh) 2018-07-13
BRPI0711767A2 (pt) 2012-01-10
EP2463297B1 (en) 2016-10-19
DK2040740T3 (da) 2014-12-01
EP2463295A1 (en) 2012-06-13
EP2474554A2 (en) 2012-07-11
JP2017137337A (ja) 2017-08-10
EP2463296A1 (en) 2012-06-13
US8404632B2 (en) 2013-03-26
CN101495134B (zh) 2016-08-03
NZ594457A (en) 2013-06-28
WO2007139791A3 (en) 2008-05-02
CN104689300A (zh) 2015-06-10
EP2032156B1 (en) 2012-11-21
ES2399662T3 (es) 2013-04-02
CA2653101C (en) 2016-12-13
CA2653080C (en) 2019-02-12
EP2474554A3 (en) 2012-10-03
NZ573004A (en) 2012-06-29
EP2032156A4 (en) 2009-11-11
HK1129688A1 (en) 2009-12-04
JP2014224156A (ja) 2014-12-04
US8404631B2 (en) 2013-03-26
ES2610653T3 (es) 2017-04-28
ES2611157T3 (es) 2017-05-05
CA2653101A1 (en) 2007-12-06
JP6118772B2 (ja) 2017-04-19
US20150266931A1 (en) 2015-09-24
US9493527B2 (en) 2016-11-15
EP2040740B1 (en) 2014-09-03

Similar Documents

Publication Publication Date Title
DK2032156T3 (da) Sammensætninger og fremgangsmåder til levering af oxygen
DK2041071T3 (da) Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade
DK2240155T3 (da) Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
DK2570467T3 (da) Sammensætninger af tetrafluorpropen og carbonhydrider
DK2470656T3 (da) Sammensætning til hæmning af genekspression og anvendelser heraf
DK2131856T3 (da) Sammensætninger og fremgangsmåder til forebyggelsen og behandlingen af autoimmune tilstande
DK2334378T3 (da) Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
DK2653873T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
DK1991678T4 (da) Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer
DK2001611T3 (da) Fremgangsmåde og sammensætning til oprensning af jord
DK2087002T3 (da) Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat
DK2099489T3 (da) Sammensætninger og fremgangsmåder til behandling af en neoplasme
DK2069352T3 (da) Bestemte kemiske enheder, sammensætninger og fremgangsmåder
DK2323638T3 (da) Sammensætninger og fremgangsmåder til behandling af osteoartritis
DK2220116T3 (da) Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
DK2029746T3 (da) Sammensætninger og fremgangsmåder til siRNA-hæmning af angiogenese
DK3263589T5 (da) Peptidsekvenser og sammensætninger
DK2222675T3 (da) 5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse
DK2066339T3 (da) Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner
DK3207941T6 (da) Fremgangsmåder og sammensætninger baseret på diphtheritoksin-interleukin-3-konjugater
DK3176159T3 (da) 4-phenyl-6-(2,2,2-trifluor-1-phenylethoxy)pyrimidin-baserede forbindelser og fremgangsmåder til anvendelse deraf
DK2114924T3 (da) Co-krystaller og farmaceutiske sammensætninger omfattende disse
DK2361090T3 (da) Sammensætninger til behandling af centralt medieret kvalme og opkastning
DK3128014T3 (da) Midler og fremgangsmåder til sterilisering af biofunktionelle sammensætninger
DK3263112T3 (da) Sammensætninger og fremgangsmåder til undertrykkelse af endometriproliferationer